CClinicalTrials.gg
CompletedNCT03519022BED IN 35Updated Jun 25, 2019

Behavioral Effects of Drugs: Inpatient (35)

An Early Phase 1 interventional study of Cocaine and Placebo oral capsule in Cocaine Use Disorder, sponsored by Craig Rush. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Craig Rush · Early Phase 1, Interventional, and Basic science

Phase
Early Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will determine the influence of methylphenidate (Metadate®) and duloxetine (Cymbalta®), alone and in combination, on the reinforcing, subjective and physiological effects of cocaine.

02

Conditions studied

  • Cocaine Use Disorder
03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Recent cocaine use

Exclusion criteria

Exclusion Criteria:

  • Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians deem clinically significant
  • Current or past histories of substance abuse or dependence that are deemed by the study physicians to interfere with study completion
  • History of serious physical disease, current physical disease, impaired cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure or current or past histories of serious psychiatric disorder that in the opinion of the study physician would interfere with study participation will be excluded from participation
  • Females not currently using effective birth control
  • Contraindications to cocaine, methylphenidate or duloxetine
04

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.

    Drug: Cocaine · Drug: Placebo oral capsule · Drug: Methylphenidate

  • Active comparator
    Duloxetine

    Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.

    Drug: Cocaine · Drug: Placebo oral capsule · Drug: Methylphenidate

Interventions

  • DrugCocaine

    The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.

  • DrugPlacebo oral capsule

    The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.

  • DrugMethylphenidate

    The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.

    Also known as: Metadate®

05

What researchers measure

Primary outcomes

  1. Reinforcing Effects of Cocaine Following Placebo Maintenance.

    Number of cocaine doses earned by subjects on a progressive ratio schedule of reinforcement.

    Time frame: Following at least 4 days of maintenance on placebo during inpatient admission.

  2. Reinforcing Effects of Cocaine Following Duloxetine Maintenance.

    Number of cocaine doses earned by subjects on a progressive ratio schedule of reinforcement.

    Time frame: Following at least 4 days of maintenance on duloxetine during inpatient admission.

  3. Reinforcing Effects of Cocaine Following Methylphenidate Maintenance.

    Number of cocaine doses earned by subjects on a progressive ratio schedule of reinforcement.

    Time frame: Following at least 4 days of maintenance on duloxetine during inpatient admission.

  4. Reinforcing Effects of Cocaine Following Methylphenidate and Duloxetine Maintenance.

    Number of cocaine doses earned by subjects on a progressive ratio schedule of reinforcement.

    Time frame: Following at least 4 days of maintenance on methylphenidate and duloxetine during inpatient admission.

Secondary outcomes

  1. Adjective Rating Scale-Sedative

    Subjects will complete the adjective rating scale during nine sessions while they are admitted to our inpatient unit. Responses to 16 items are summed (total score=0-64; Higher values=more sedation) to calculate scores on a sedative subscale.

    Time frame: Nine times over approximately four weeks inpatient admission.

  2. Adjective Rating Scale-Stimulant

    Subjects will complete the adjective rating scale during nine sessions while they are admitted to our inpatient unit. Responses to 16 items are summed (total score=0-64; Higher values=more stimulation) to calculate total scores on a stimulant subscale.

    Time frame: Nine times over approximately four weeks inpatient admission.

  3. Drug Effect Questionnaire

    Subjects will complete the drug effect questionnaire during nine sessions while they are admitted to our inpatient unit. The items (total scores=0-100; Higher scores=greater drug effect) on this scale categorize the constellation of drug effects endorsed by subjects.

    Time frame: Nine times over approximately four weeks inpatient admission.

  4. Heart rate

    Beats per minute. Measured daily during inpatient admission.

    Time frame: Daily over approximately four week inpatient admissions.

  5. Blood pressure

    mmHg.Measured daily during inpatient admission.

    Time frame: Daily over approximately four week inpatient admissions.

  6. Temperature

    Degrees fahrenheit. Measured daily during inpatient admission.

    Time frame: Daily over approximately four week inpatient admissions.

  7. Side effects

    Subjects will complete a side effects questionnaire daily while they reside on the inpatient unit. Side Effects questions will query subjects about common effects of centrally active medications.

    Time frame: Daily over approximately four week inpatient admissions.

  8. Delay Discounting Task

    Subjects will complete the delay discounting task during nine sessions while they are admitted to our inpatient unit. Responses will be used to calculate discounting slope (i.e., K).

    Time frame: Nine times over approximately four weeks inpatient admission.

  9. Attentional Bias

    Subjects will complete attentional bias during nine sessions while they are admitted to our inpatient unit. Time attending to drug stimuli will be used to evaluate attentional bias.

    Time frame: Nine times over approximately four weeks inpatient admission.

  10. Inhibitory Control

    Subjects will complete an inhibitory control task during nine sessions while they are admitted to our inpatient unit. Ability to inhibit prepotent responding will be used to calculate inhibitory control.

    Time frame: Nine times over approximately four weeks inpatient admission.

06

Study locations

1 site
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536-0086, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03519022
Lead sponsor
Craig Rush
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
Craig Rush (Professor, University of Kentucky) — Sponsor-investigator
First posted
May 8, 2018
Start date
Jun 1, 2018
Primary completion
May 31, 2019
Completion
May 31, 2019
Last update
Jun 25, 2019

Study contacts

Craig R Rush, PhD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion